Anti-14G2a mAbs [1A7](MABL-150)

MABL-150

activation, FACS, neutralizing, Therapeutics development, FC

Engineer antibody

Mouse

1A7

Recombinant Antibody

This antibody is specific for an idiotype of the anti-ganglioside GD2 antibody 14G2a and behaves as an internal image of GD2.

antibody 14G2a; idiotype of 14G2a; anti-ID; GD2; ganglioside GD2; disialoganglioside GD2

The anti-idiotypic antibody 1A7 was raised by immunizing BALB/c mice with a mouse anti- GD2 antibody 14G2a.

Various cancers, such as melanoma, neuroblastoma, glioma, soft tissue sarcoma, and small cell carcinoma, involve overexpression of ganglioside GD2. Traditional therapeutic approaches comprised attempts to administer anti-GD2 antibodies to deplete the cancer cells. However, such interventions often lead to the development of the immune response against those therapeutic antibodies or the cytotoxic activation against the tumor cells caused by the therapeutic was insufficient. The solution to this problem might be the generation of an anti-idiotypic antibody (Ab2) against a primary antibody that can bind GD2 (Ab1). Such an anti-idiotypic antibody (Ab2) works as an internal image of the antigen (GD2) and, upon administration to a subject with a Gd2-positive tumor, can lead to the generation of anti-anti- idiotypic antibodies (Ab3), which will be directed against GD2 and will lead to the depletion of the tumor. This antibody is such an anti-idiotypic antibody (Ab2) that it was demonstrated to functionally mimic the tumor-associated antigen disialoganglioside GD2. This antibody was shown to be able to induce the production of the anti-anti-idiotypic antibodies (Ab3) directed against GD2 in mice, rabbits, and nonhuman primates. It was capable of reacting with the GD2-positive melanoma cell line M21/P6 cells but not with GD2-negative LS174-T cells (Sen et al., 1997; PMID: 9815586). In a phase I clinical trial immunization of patients with this antibody, mixed with the adjuvant QS21, demonstrated that this antibody could act as a surrogate antigen for GD2 and induce strong humoral immune responses in advanced-stage melanoma patients (Zeytin et al., 2000; PMID: 11129285). Consequently, this clone can be further recommended for the development of effective approaches targeting GD2-positive cancers. This antibody was used for flow cytometry (FC) to detect chimeric antigen receptor (CAR) expression by transduced T lymphocytes (Yvon et al., 2009; PMID: 19737958). Dylight 650- or 488-conjugated antibody was used to measure T-cell transduction in flow cytometry analysis. This antibody was also used as a proliferation stimulus in MDSC(myeloid-derived suppressor cell) suppression assays to evaluate the suppressive effects of MDSCs on T- cell proliferation (Long et al., 2016; PMID: 27549124). This antibody was used to detect the GD2 CAR in flow cytometry analysis (Labanieh et al., 2022; PMID: 35483375). This antibody was used to sort cells expressing the GD2-specific CARs in FACS (Lamarche et al., 2023; PMID: 36972454).

Sen et al. Preclinical evaluation in nonhuman primates of murine monoclonal anti-idiotype antibody that mimics the disialoganglioside GD2 Clin Cancer Res. 1997 Nov;3(11):1969-76. PMID:9815586

Describes the generation, characterization and preclinical trials of the anti-idiotypic antibody 1A7.

100 μg Purified antibody.

1 mg/ml.

Protein A affinity purified

PBS with 0.02% Proclin 300.

Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C.